Muscle Perfusion and Protein Metabolism in Elderly

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of this study was to examine the role skeletal muscle perfusion plays in mediating muscle protein synthesis in healthy older and younger individuals. The investigators hypothesized that normalization of muscle perfusion in older men and women via exercise or infusion of a vasodilator would enhance nutritive flow and skeletal muscle protein synthesis in the elderly similar to that of their younger counterparts.

Condition or disease	Intervention/treatment	Phase
Aging	Other: Aerobic Exercise; Drug: Sodium Nitroprusside; Dietary Supplement: Amino Acid Drink	Phase 1

Detailed Description:

The purpose of this study was to examine muscle protein metabolism in healthy young and elderly subjects during pharmacologic vasodilation of the lower limb vasculature in combination with increased amino acids delivery. We obtained femoral arteriovenous blood samples and v. lateralis muscle biopsies during a primed continuous infusion of L-[ring-13C6] Phenylalanine. Muscle protein kinetics were measured in the basal state and during a 180 min infusion of sodium nitroprusside (SNP) and amino acids (Premsol 10%) (SNP+AA). Skeletal muscle microvascular recruitment and flow were measured during the basal state and SNP+AA using contrast-enhanced ultrasound (CEU).

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	62 participants
Allocation:	Randomized
Intervention Model:	Factorial Assignment
Masking:	None (Open Label)
Official Title:	A Phase I Trial Examining Muscle Perfusion and Protein Metabolism in Elderly and Young
Study Start Date :	May 2003
Actual Primary Completion Date :	May 2008
Actual Study Completion Date :	May 2009

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: Young Aerobic Exercise; 45 minutes of treadmill walking at 40% VO2 peak	Other: Aerobic Exercise; 45 minuties of treadmill walking was completed at 40% VO2 peak
Active Comparator: Elderly Aerobic Exercise; 45 minutes of treadmill walking at 40% VO2 peak	Other: Aerobic Exercise; 45 minuties of treadmill walking was completed at 40% VO2 peak
Active Comparator: Young Sodium Nitroprusside; Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min	Drug: Sodium Nitroprusside; Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min; Other Name: Nitropress
Active Comparator: Elderly Sodium Nitoprusside; Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min	Drug: Sodium Nitroprusside; Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min; Other Name: Nitropress
Active Comparator: Elderly Sodium Nitroprusside and Amino Acid Drink; Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally	Drug: Sodium Nitroprusside; Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min; Other Name: Nitropress; Dietary Supplement: Amino Acid Drink; 7.5 gram Amino Acid drink

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Mixed Muscle Fractional Synthesis Rate (FSR) [ Time Frame: Acute ( 8 hours) ]
   The rate at which the body makes new muscle was assessed by determining the fractional synthesis rate (FSR). This technique determines how quickly new amino acids are used to make muscle. In this technique, a special (but natural and non-radioactive) version of an amino acid is infused into the blood. This special version of the amino acid is heavier than the most common version the same amino acid. This property allows it to be identified in a muscle sample. By determining how much of the special amino acid has accumulated over time in a muscle sample, the fractional synthesis rate can be determined. For example, if the rate were such that 1 of every 100 amino acids were of the special type after 1 day, the fractional synthesis rate would be 1% per day. In other words, 1/100 of the muscle would be newly made each day.

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

All inclusion criteria must be fulfilled throughout the study. At enrollment, subjects must fit the following criteria:

1. Age: young 18-40 yrs; elderly 60-85 yrs.
2. Availability of transportation (i.e., subjects must be able to provide their own transportation to UTMB).
3. Ability to sign informed consent (score >24 on 30 item mini-mental status exam and no errors on assessment of judgment).

Exclusion Criteria:

None of the following exclusion criteria should be present at enrollment or throughout the study:

1. Patients with limiting or unstable angina or who demonstrate cardiac abnormalities such as > 0.2 mV horizontal or downsloping ST segment depression, frequent arrhythmias (>10 PVC/min), or valvular disease.
2. Any patient with atrial fibrillation, history of syncope, angina, or congestive heart failure.
3. Patients with vascular disease, as determined by the presence of risk factors of peripheral atherosclerosis (i.e., hypertension, obesity, uncontrolled diabetes, and evidence of venous or arterial insufficiency upon palpation of femoral, popliteal, and pedal arteries).
4. Peripheral vascular disease as determined by history or abnormal ankle-brachial index by Doppler (< 1.0).
5. Any subject with blood pressure on three consecutive measurements taken at rest on separate occasions that has a systolic pressure >170 mm Hg or a diastolic blood pressure >100 mm Hg will be excluded. Subjects will not be included if they are taking blood pressure medication and have a blood pressure above these criteria.
6. Any person HIV-seropositive, with active hepatitis, or any other immunosuppressive or autoimmune disease.
7. Any patient taking beta blockers, vasodilators, angiotensin-converting enzyme inhibitors, calcium channel blockers, or alpha blockers.
8. Any patient with uncontrolled metabolic diseases including any patient with liver or renal disease.
9. Glucose intolerance: fasting plasma glucose concentration 110-126 mg/dL (6.1-7 mmol/L) and/or 2-h plasma glucose 140-200 mg/dL (7.8-11.1 mmol/L) during oral glucose tolerance test (OGTT).
10. Currently in muscle strengthening program.
11. Total knee replacement or moderate to severe degenerative joint disease of knees.
12. Anemia (hemoglobin <13 g/dL in males or <12 g/dL in females).
13. Any history of hypo- or hyper-coagulation disorders, including patients taking Coumadin or with a history of deep venous thrombosis (DVT) or pulmonary embolism (PE) at any point in their lifetimes.
14. Currently taking aspirin and cannot stop for 7 days (i.e., medical indication for continued aspirin such as transient ischemic attacks).
15. Presence of acute illness or metabolically unstable chronic illness.
16. Heart disease requiring therapy or recent myocardial infarction (less than 1 year)
17. Currently on weight-loss diet.
18. Active cancer or in short-term remission (less than 3 years).
19. Alcohol or drug abuse.
20. History of >20 packs per year cigarette smoking.
21. Recent (within 6 months) ingestion or injection or transdermal administration of anabolic steroids, corticosteroids, estrogens, or progestagens.
22. History of falls (1 fall in the past year which required medical attention, or more than 2 falls/year regardless of severity).
23. Allergy to iodides, penicillin or shellfish.
24. Any subject with a know hypersensitivity to octafluoropropane.
25. Any subject with a cardiac shunt.
26. Any subject with chronic obstructive pulmonary disease (COPD).

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Sponsors and Collaborators

The University of Texas Medical Branch, Galveston

National Institute on Aging (NIA)

Investigators

Principal Investigator:	Melinda Sheffield-Moore, PhD	UTMB

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier:	NCT00945256 History of Changes
Other Study ID Numbers:	03-213; R01AG021539 ( U.S. NIH Grant/Contract )
First Posted:	July 24, 2009
Results First Posted:	January 5, 2016
Last Update Posted:	February 3, 2016
Last Verified:	April 2014

Keywords provided by The University of Texas Medical Branch, Galveston:

metabolism; exercise; sodium nitroprusside

Additional relevant MeSH terms:

Nitroprusside; Antihypertensive Agents; Vasodilator Agents; Nitric Oxide Donors; Molecular Mechanisms of Pharmacological Action